Ginkgo Bioworks DNA Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$297.87M+4.8% | -$312.76M+7.9% | -$339.55M-7.7% | -$315.19M+33.2% | -$472.08M+13.7% | ||
| $56.97M-3.4% | $58.99M-3.3% | $60.98M-4.7% | $63.98M-1.5% | $64.97M+3.1% | ||
| $80.01M-1.9% | $81.55M+0.6% | $81.08M+5.2% | $77.09M-13.3% | $88.95M-20.8% | ||
| —— | -$1.36M-8.5% | -$1.26M-9.3% | -$1.15M-10.3% | -$1.04M-11.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | $7.65M+114% | -$56.43M-33.0% | -$42.44M-5.0% | ||
| —— | —— | —— | —— | —— | ||
| $11.4M-6.2% | $12.16M+132% | $5.25M— | —— | —— | ||
| -$2.2M-1.7% | -$2.17M+5.1% | -$2.28M— | —— | —— | ||
| -$21.81M+32.7% | -$32.39M-15.4% | -$28.08M+62.7% | -$75.31M+4.6% | -$78.92M-15.0% | ||
| $29.82M-0.9% | $30.08M+0.5% | $29.93M+0.1% | $29.89M+0.2% | $29.84M+6.2% | ||
| -$28.14M-0.7% | -$27.93M-25.3% | -$22.29M+1.6% | -$22.65M-43.3% | -$15.81M-4.6% | ||
| -$166.22M+2.8% | -$171.06M-3.2% | -$165.82M+30.2% | -$237.71M+15.7% | -$281.85M+11.8% | ||
| $1.98M-74.2% | $7.67M-64.1% | $21.37M-41.4% | $36.46M-42.5% | $63.45M+1.5% | ||
| $310.61M-25.8% | $418.63M+4.2% | $401.84M+25.5% | $320.13M+67.4% | $191.18M— | ||
| $134.08M+418% | $25.9M+756% | -$3.95M-106% | $64.96M— | —— | ||
| —— | —— | -$511K+16.1% | -$609K+7.4% | -$658K-22.3% | ||
| —— | —— | -$348.47M-21.9% | -$285.86M-14.9% | -$248.81M-300% | ||
| $166K-53.1% | $354K-33.5% | $532K-24.9% | $708K-12.6% | $810K-9.7% | ||
| —— | $0— | $0— | $0— | $0— | ||
| $17.96M+1.1% | $17.78M+88.5% | $9.43M+1,069% | -$973K+11.6% | -$1.1M+36.7% | ||
| —— | —— | $280K+84.2% | $152K+404% | -$50K+82.2% | ||
| —— | —— | -$504.58M+3.8% | -$524.39M+1.4% | -$531.81M-38.5% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$28.14M-0.7% | -$27.93M-25.3% | -$22.29M+1.6% | -$22.65M-43.3% | -$15.81M-4.6% | ||
| —— | —— | $7.65M+114% | -$56.43M-33.0% | -$42.44M-5.0% | ||
| $11.4M-6.2% | $12.16M+132% | $5.25M— | —— | —— | ||
| —— | —— | —— | -$6.04M+27.6% | -$8.35M+17.2% | ||
| —— | —— | —— | -$12.9M+52.5% | -$27.14M-15.7% | ||
| —— | $0+100% | -$279.25K+50.0% | -$558.5K+33.3% | -$837.75K+25.0% | ||
| $29.82M-0.9% | $30.08M+0.5% | $29.93M+0.1% | $29.89M+0.2% | $29.84M+6.2% | ||
| -$2.2M-1.7% | -$2.17M+5.1% | -$2.28M— | —— | —— | ||
| —— | —— | -$511K+16.1% | -$609K+7.4% | -$658K-22.3% | ||
| —— | $0— | $0— | $0— | $0— | ||
| —— | —— | —— | —— | —— | ||
| $166K-53.1% | $354K-33.5% | $532K-24.9% | $708K-12.6% | $810K-9.7% | ||
| —— | —— | —— | —— | —— | ||
| -$21.81M+32.7% | -$32.39M-15.4% | -$28.08M+62.7% | -$75.31M+4.6% | -$78.92M-15.0% | ||
| -$28.14M-0.7% | -$27.93M-25.3% | -$22.29M+1.6% | -$22.65M-43.3% | -$15.81M-4.6% | ||
| -$168.2M+5.9% | -$178.72M+4.5% | -$187.19M+31.7% | -$274.17M+20.6% | -$345.3M+9.6% | ||
| -$168.2M+5.9% | -$178.72M+4.5% | -$187.19M+31.7% | -$274.17M+20.6% | -$345.3M+9.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does Ginkgo Bioworks generate?
- Ginkgo Bioworks (DNA) generated -$166.2M in operating cash flow over the trailing twelve months.
- What is Ginkgo Bioworks's free cash flow?
- After $2.0M of capital expenditures, Ginkgo Bioworks's free cash flow was -$168.2M over the trailing twelve months, up 51.3% year over year.
- Where does Ginkgo Bioworks's cash flow data come from?
- Every line is extracted from Ginkgo Bioworks's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
